Phase II Study on TSR-042 in Advanced Clear Cell Sarcoma
Latest Information Update: 11 Mar 2024
Price :
$35 *
At a glance
- Drugs Dostarlimab (Primary)
- Indications Clear cell sarcoma
- Focus Therapeutic Use
- Acronyms ACCeSs
- 31 Jan 2024 Status changed from active, no longer recruiting to discontinued.
- 06 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 29 Oct 2021 Status changed from active, no longer recruiting to recruiting.